Floriane Samaria

Floriane Samaria

Auto-generated profile, based on publicly available information

Floriane Samaria

Univ. Bordeaux - Inserm U1219

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2026 in medRxiv
Verified
Preprint
Open access
GMGaëlle Munsch
Gaëlle Munsch
CPCarole Proust
Carole Proust
CRCatherine E Richter
Catherine E Richter
MGMarine Germain
Marine Germain
MTMaud Tusseau
Maud Tusseau
OSOmar Soukarieh
Omar Soukarieh
Endoglin is a transmembrane glycoprotein that plays a key role in vascular development, angiogenesis and endothelial homeostasis. Its soluble form (Sol-ENG), generated through proteolytic shedding of the membrane-bound protein, has been implicated in the pathophysiology of numerous cardiovascular diseases, ranging from common conditions such as preeclampsia and thrombosis to rare diseases such as hereditary hemorrhagic telangiectasia (HHT). Leveraging large-scale genomics, transcriptomics, proteomics and metabolomics data from public and original resources, we identify a molecular signature of 24 markers associated with plasma levels of Sol-ENG. This signature was enriched in genes coding for GPI-enchored proteins and included metabolites participating to glycosylation and redox homeostasis. Furthermore, we observed that ABO blood groups and genetically predicted plasma levels of 5-Azacytidine Induced 2 (AZI2) associate with the risk of arteriovenous malformations in HHT patients. This study provides new insights into the physiological mechanisms underlying Endoglin regulation and opens clinical perspectives for the management of HHT patients.

31 March 2026 in Blood Vessels, Thrombosis & Hemostasis
Verified
Journal Article
Open access
FSFloriane Samaria
Floriane Samaria
OBOhanna Cavalcanti de Lima Bezerra
Ohanna Cavalcanti de Lima Bezerra
LGLénaïck Gourhant
Lénaïck Gourhant
MGMarine Germain
Marine Germain
GMGaëlle Munsch
Gaëlle Munsch
DTDavid-Alexandre Trégouët
David-Alexandre Trégouët
• RPVO is observed in ∼30% patients with unprovoked PE and is associated with long-term complications such as recurrent PE and chronic thromboembolic pulmonary hypertension. • Although ABO is a known risk factor for PE recurrence and chronic thromboembolic pulmonary hypertension, this work shows that ABO has little to no influence on the risk of RPVO.

14 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
FSFloriane Samaria
Floriane Samaria
OBOhanna Cavalcanti de Lima Bezerra
Ohanna Cavalcanti de Lima Bezerra
LGLénaïck Gourhant
Lénaïck Gourhant
MGMarine Germain
Marine Germain
GMGaëlle Munsch
Gaëlle Munsch
DTDavid-Alexandre Trégouët
David-Alexandre Trégouët
Background: After completing anticoagulant therapy for acute pulmonary embolism (PE), patients may have persistent thrombotic materials in the lung, causing residual pulmonary vascular obstruction (RPVO). Detectable by imaging, RPVO is associated with an increased risk of recurrent events and chronic complications. Identifying RPVO risk factors has become a recent focus, yet no genetic determinants have been established. This study specifically investigates the association between genetically determined ABO blood groups and RPVO in patients with unprovoked-PE. Methods: This work relies on two French cohorts of patients with unprovoked-PE, EDITH and PADIS-PE, and a Canadian one, REVERSE-I, where RPVO was measured with the same protocol. In each study, five ABO polymorphisms were used to infer ABO blood groups: rs8176719-delG, rs41302905-T, rs2519093-T, rs1053878-A and rs8176743-T alleles tagging for O1, O2, A1, A2 and B, respectively. Associations between ABO blood groups and RPVO were assessed in each study using a Compound Poisson Gamma model, which accounts for the semi-continuous RPVO distribution. Study-specific results were then combined through meta-analysis. Results: The meta-analysis included 586 patients with unprovoked-PE, providing sufficient power (>80%), as confirmed by simulations, to detect moderate genetic effects (1.3-fold increased risk) of common variants (allele frequency ≥0.05). Despite this, no significant association was observed between ABO blood groups and RPVO, and no consistent effect was seen across the three studies. Interpretation: ABO blood groups are unlikely to be major risk factors for RPVO. Nevertheless, this study provides an important foundation for future large-scale genetic investigations aimed at identifying the molecular determinants of RPVO.

8 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
FSFloriane Samaria
Floriane Samaria
GMGaelle Munsch
Gaelle Munsch
OBOhanna Cavalcanti de Lima Bezerra
Ohanna Cavalcanti de Lima Bezerra
KWKerri L Wiggins
Kerri L Wiggins
LGLenaick Gourhant
Lenaick Gourhant
DTDavid-Alexandre Tregouet
David-Alexandre Tregouet
Background and Aims: Residual pulmonary vascular obstruction (RPVO) defined as the persistence of thrombotic material within the pulmonary arteries several months after an acute pulmonary embolism (PE) is associated with an increased risk of severe complications, including recurrent events and chronic pulmonary hypertension. However, the genomic architecture underlying RPVO in unprovoked PE remains poorly understood, and this study aims to address this gap. Method: By leveraging genetic and imaging RPVO data from three independent cohorts totaling 586 unprovoked PE patients, we conducted a meta-analysis of genome wide association study (GWAS) of RPVO using a dedicated statistical method to handle the semi-continuous distribution of RPVO. The meta-GWAS was complemented by haplotype association analyses and transcriptome wide association studies as well as Mendelian Randomization (MR) approaches based on plasma metabolites and proteins. Results: Through meta-GWAS, we identified one locus, OSTN, associated with RPVO (lead variant rs59109356 associated with a ~2-fold increase of RPVO, p=3.92x10-8). A second locus, CCN4, previously reported to associate with pulmonary fibrosis, was also identified, with evidence of association approaching genome-wide significance (p=6.7x10-8). We also identified a common haplotype spanning over AHSG/HRG/KNG1 associated with a ~3-fold increase of RPVO (p=2.96x10-8). Using plasma protein-based MR, we demonstrated that one unit increase in genetically determined plasma levels of IL-1 R AcP encoding IL1RAP was associated with a 28% (p=1.32x10-6) reduction in RPVO. We also observed statistical evidence that the CCN4 (p=0.06) and IL1RAP (p=0.02) loci associate with the risk of PE recurrence in a sample of 1,617 unprovoked PE patients. Conclusions: By identifying novel molecular determinants of RPVO that map to loci involved in inflammatory pathways and vascular remodeling, our study provides evidence that inflammation is the predominant, and likely the key mechanism underlying RPVO, whereas impaired fibrinolysis appears to play a more limited role.